(Q37077629)

18 August 2017

1 reference

title

Pharmacologic options for CNS infections caused by resistant Gram-positive organisms (English)

1 reference

18 August 2017

main subject

gram-positive bacteria

0 references

1 reference

William J Peppard

1

1 reference

18 August 2017

Carolyn J Johnston

series ordinal

2

1 reference

18 August 2017

Angela M Urmanski

series ordinal

3

1 reference

18 August 2017

publication date

1 February 2008

1 reference

Expert Review of Anti-infective Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

6

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

83-99

1 reference

Risk factors associated with postcraniotomy meningitis.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Infections complicating the use of external ventriculostomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Ventriculostomy-related infections: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Ventriculostomy-related infections. A prospective epidemiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Ventriculostomy and intracranial pressure monitoring: in search of a 0% infection rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Prophylactic antibiotics with intracranial pressure monitors and external ventricular drains: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Ventriculostomy-associated infections: incidence and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infectious pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Infection of cerebrospinal fluid shunts in infants: a study of etiological factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Bacterial meningitis: pathogenesis, pathophysiology, and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Practice guidelines for the management of bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

The impact of methicillin-resistant Staphylococcus aureus in a neurosurgical unit: a growing problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Central Nervous System Infections in the Immune-competent Adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Pharmacokinetics and pharmacodynamics of antibiotics in meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

The penetration of anti-infectives into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

The emergence and evolution of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Staphylococcus aureus with reduced susceptibility to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

The pharmacokinetic and pharmacodynamic properties of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Linezolid for the treatment of central nervous system infections in neurosurgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Successful treatment with linezolid and rifampicin of meningitis due to methicillin-resistant Staphylococcus epidermidis refractory to vancomycin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Treatment of central nervous system infection by vancomycin-resistant enterococcus faecium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Clinical experience with linezolid for the treatment of central nervous system infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Clinical experience with linezolid for the treatment of nocardia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Linezolid in the treatment of brain abscess due to Peptostreptococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Sensorineural hearing loss associated with intrathecal vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Quinupristin/dalfopristin in neonatal Enterococcus faecium meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Overview of antibiotic use and resistance: setting the stage for tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

The pharmacokinetic and pharmacodynamic profile of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Vancomycin: does it still have a role as an antistaphylococcal agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

21 January 2018

Vancomycin: a history

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Linezolid for the treatment of patients with central nervous system infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Origin, structure, and activity in vitro and in vivo of dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Dalbavancin: a novel lipoglycopeptide antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Ceftobiprole: in-vivo profile of a bactericidal cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Clinical profile of ceftobiprole, a novel beta-lactam antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Dihydrofolate reductase inhibitors as antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.83

21 January 2018

Identifiers

DOI

10.1586/14787210.6.1.83

1 reference

18 August 2017

1 reference